Post-marketing Surveillance Study With MicardisPlus® in Treatment of Morning Hypertension (Self-monitored by Patient)

Morning Hypertension and Patient Self-monitoring

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT02243566

Enrollment

2707

Registered

2014-09-18

Start date

2006-04-30

Completion date

Unknown

Last updated

2014-09-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hypertension

Brief summary

The purpose of the study was to examine the effect of six- to eight-week treatment with MicardisPlus® on blood pressure and the effect of patient self-monitoring on blood pressure control. In addition, the post-marketing surveillance study offered the possibility to obtain information about the influence on different laboratory parameters during treatment with MicardisPlus® from an unselected patient group under office conditions

Interventions

DRUGMicardisPlus®

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Age \> 18 years * Hypertension

Exclusion criteria

* Age \< 18 years

Design outcomes

Primary

Measure	Time frame
Number of patients with adverse events	Up to 8 weeks
Changes in morning blood pressure (systolic and diastolic)	Pre-dose, up to 8 weeks after start of treatment
Changes from baseline in laboratory values	Pre-dose, up to 8 weeks after start of treatment
Investigator assessment of efficacy on a 5-point scale	Up to 8 weeks after start of treatment
Investigator assessment of influence on metabolism on a 3-point scale	Up to 8 weeks after start of treatment
Investigator assessment of tolerability on a 5-point scale	Up to 8 weeks after start of treatment

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026